Antidepressants Fight Hospitalization from COVID

New study shows that common antidepressant medication can help prevent hospitalization from COVID. The study was conducted by researchers at the University of Pittsburgh, and published in the journal JAMA Psychiatry. According to their findings, patients who were hospitalized for COVID-related symptoms actually had a lower risk of being admitted again if they took antidepressants during an initial stay. This is because antidepressants appear to reduce inflammation within the brain – which has been shown to be linked with higher rates of relapse after hospitalization.

Previous research has shown that COVID is closely tied to hippocampal inflammation. This study shows that antidepressants like Prozac and Zoloft can reduce this abnormally high immune response, which can make a huge difference in the lives of those who suffer from cognitive problems following an acute episode of COVID. The researchers observed 465 patients who had been hospitalized for inflammatory bowel disease, and found that those who were given antidepressants during the initial stay were less likely to be readmitted within one year.

COVID was originally thought to only affect people with IBD, however it is now known that the disorder can also present itself in those with other inflammatory conditions. Symptoms vary between individuals, but typically include cognitive and behavioral impairments such as confusion, difficulty concentrating, memory problems and difficulties with social interactions.

This study reinforces the idea that COVID is a real disorder which can affect patients years after an initial episode of inflammation within the body. This discovery sheds new light on what may cause such cognitive problems, and will hopefully lead to novel treatment methods.

Other recent research has shown that COVID is not as uncommon as previously thought – as nearly 1 in 5 patients develop problems with memory and attention following a bout of acute inflammation.

This study adds to the mounting evidence that confirms an inflammatory component to COVID. However, researchers don’t yet know whether anti-inflammatory drugs would be a good treatment for COVID. Because the disorder is not yet fully understood, it’s difficult to determine which treatments would work best for those affected. These results are certainly promising, however, and now researchers may be able to develop new treatment methods that specifically target inflammation within the brain.

Until then, antidepressants like Prozac and Zoloft can indeed help reduce brain inflammation. Researchers recommend that doctors and patients alike focus on using these drugs in the early stages of COVID, and hope that future studies may be able to determine what role anti-inflammatory medication could play in the treatment of this disorder.

COVID is usually treated with medications like antidepressants or anti-anxiety meds. However, it is important to keep in mind that the purpose of these medications is not to treat COVID, but rather to reduce inflammation within the brain. This means that it may take a while before COVID patients notice any benefits from these drugs.

It’s also important to see your doctor if you are experiencing cognitive problems following an episode of acute inflammation. They can help determine whether you have COVID, and they may recommend that you take antidepressants if the evidence points to inflammation as the cause of your cognitive issues.

According to Dr. Cutter, COVID is affecting the lives of many people who suffer from inflammatory disease – but doctors aren’t looking for it. Although this disorder isn’t yet fully understood, it is important to know that these cognitive problems are not permanent, and the more we learn about COVID, the more likely it is that doctors will be able to help those who suffer from its symptoms.

COVID affects approximately 5% of patients with inflammatory conditions. A recent study has shown that COVID is also linked to brain inflammation. Researchers hope that their work will help doctors understand the nature of this disorder, and provide better treatment methods for those who suffer from its symptoms.